Cargando…
Human Vaccines & Immunotherapeutics: News
Efficacy and safety of first-ever Dengue vaccine candidate in Phase 3 Agenus‘ brain cancer vaccine doubles survival rate in GBM patients New study: Rotavirus vaccines dramatically cut hospitalization rates in US children Therapeutic vaccines – from heart disease to cancer Agenus‘ genital herpes vacc...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896771/ https://www.ncbi.nlm.nih.gov/pubmed/25424916 http://dx.doi.org/10.4161/hv.36804 |
| _version_ | 1782436038976733184 |
|---|---|
| author | Riedmann, Eva M |
| author_facet | Riedmann, Eva M |
| author_sort | Riedmann, Eva M |
| collection | PubMed |
| description | Efficacy and safety of first-ever Dengue vaccine candidate in Phase 3 Agenus‘ brain cancer vaccine doubles survival rate in GBM patients New study: Rotavirus vaccines dramatically cut hospitalization rates in US children Therapeutic vaccines – from heart disease to cancer Agenus‘ genital herpes vaccine significantly reduces viral burden in Phase 2 The latest on PaxVax‘ and Gotovax AB’s cholera vaccine candidates ACIP ponders recommendation for Prevnar use in seniors |
| format | Online Article Text |
| id | pubmed-4896771 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-48967712016-06-24 Human Vaccines & Immunotherapeutics: News Riedmann, Eva M Hum Vaccin Immunother News, Policy & Profiles Efficacy and safety of first-ever Dengue vaccine candidate in Phase 3 Agenus‘ brain cancer vaccine doubles survival rate in GBM patients New study: Rotavirus vaccines dramatically cut hospitalization rates in US children Therapeutic vaccines – from heart disease to cancer Agenus‘ genital herpes vaccine significantly reduces viral burden in Phase 2 The latest on PaxVax‘ and Gotovax AB’s cholera vaccine candidates ACIP ponders recommendation for Prevnar use in seniors Taylor & Francis 2014-10-10 /pmc/articles/PMC4896771/ /pubmed/25424916 http://dx.doi.org/10.4161/hv.36804 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| spellingShingle | News, Policy & Profiles Riedmann, Eva M Human Vaccines & Immunotherapeutics: News |
| title | Human Vaccines & Immunotherapeutics: News |
| title_full | Human Vaccines & Immunotherapeutics: News |
| title_fullStr | Human Vaccines & Immunotherapeutics: News |
| title_full_unstemmed | Human Vaccines & Immunotherapeutics: News |
| title_short | Human Vaccines & Immunotherapeutics: News |
| title_sort | human vaccines & immunotherapeutics: news |
| topic | News, Policy & Profiles |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896771/ https://www.ncbi.nlm.nih.gov/pubmed/25424916 http://dx.doi.org/10.4161/hv.36804 |
| work_keys_str_mv | AT riedmannevam humanvaccinesimmunotherapeuticsnews |